2018 Porphyria Safe List

We are pleased to share the 2018 version of the Porphyria Safe List. We have made the following changes to the list this year:

  • No drugs have been removed from the list due to concerns about safe use in porphyria.
  • Iodine-based contrast media has been removed in favour of the group name Contrast media (gadolinium- or iodine-based)

The following medicines have been added as SAFE:

  • Aflibercept
  • Glucagon-like peptide-1 (GLP-1) receptor agonists (dulaglutide, exenatide, liraglutide, lixisenatide)
  • Tolvaptan

An additional category of Antidiabetics has been added to the treatment options groupings.

Please note that we are unable to reply to porphyria enquiries by email or fax for confidentiality reasons. Our specialists will need a contact telephone number to discuss our advice with you.

I hope you find this list useful. If you require any further advice about the safety of drugs used in acute porphyria, please do not hesitate to contact the centre on 029 2074  4181.

Please be assured that any information you share with us is held safely and securely. The new General Data Protection Regulations come into effect on 25 May 2018. In order for us to send you future safe list updates, you need to opt-in to receive communications from us. Please do this either by completing the opt in form or calling 029 2074 4298.

Translate to Welsh »